Interferon-ribavirin for chronic hepatitis C with and without cirrhosis: Analysis of individual patient data of six controlled trials
Journal
Gastroenterology
Journal Volume
117
Journal Issue
2
Pages
408-413
Date Issued
1999
Author(s)
Schalm S.W.
Weiland O.
Hansen B.E.
Milella M.
Lai M.Y.
Hollander A.
Michielsen P.P.
Bellobuono A.
Chemello L.
Pastore G.
Brouwer J.T.
Braconnier J.H.
Fryden A.
Norkrans G.
Reichard O.
Adler M.
Chamuleau R.A.F.M.
Delwaide J.
Elewaut A.
Fevery J.
Hautekeete M.L.
Nevens F.
Den Ouden-Muller J.W.
Wismans P.J.
Casalino C.
Maselli R.
Pietromatera G.
Chan K.W.
Ideo G.
Alberti A.
Cavalletto L.
Boot J.
Van Vliet C.
Abstract
Combination with ribavirin significantly enhances the sustained response rate of IFN therapy in major patient types (cirrhosis, genotype 1) with chronic hepatitis C. Thus, IFN-ribavirin combination is likely to become the antiviral therapy of choice for cirrhosis caused by hepatitis C.
SDGs
Publisher
W.B. Saunders
Type
journal article